CD8+ lymphocyte responses to antiretroviral therapy of HIV infection

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue 4, 1996, Pages 320-326

  Carr, Andrew ^a   Emery, Sean ^b   Kelleher, Anthony ^a   Law, Matthew ^b   Cooper, David A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

CD8+ lymphocyte; HIV; Prognosis; Viral load

Indexed keywords

ANTIVIRUS AGENT; CD8 ANTIGEN; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; LAMIVUDINE; LOVIRIDE; NEVIRAPINE; PLACEBO; RITONAVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROVIRUS; TREATMENT OUTCOME; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 0029809517     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199612010-00004     Document Type: Article

References (28)

1. Cooper DA, Tindall B, Wilson EJ, Imrie AA, Penny R. Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus. J Infect Dis 1988;157:889-96.
2. Tindall B, Carr A, Cooper DA. Primary HIV infection. In: Sande M, Volberding P, eds. The Medical Management of AIDS 1994. Philadelphia: WB Saunders.
3. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987;328:345-8.
4. Walker CM, Moody DJ, Stites DP, Levy JA. CDS+ cells can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-6.
5. Cocchi F, de Vico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1a and MIP-1b as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-6.
6. Baier M, Werner A, Bannert N, Metzner K, Kurth R: HIV suppression by interleukin-16. Nature 1995;378:563.
7. Koup R, et al. Temporal association of cellular immune responses with the initial control of viremia in primary HIV-1 syndrome. J Virol 1994;68:4650-5.
8. Koup RA, Ho DD. Shutting down HIV. Nature 1994;370: 416.
9. Walker BD, Plata E. Cytotoxic T lymphocytes against HIV. AIDS 1990;4:177-84.
10. + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993;69:106-16.
11. Fahey J, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
12. Moss AM, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS and AIDS related condition: three follow-up of the San Francisco General Hospital cohort. BMJ 1988;296:745-50.
13. + lymphocytes in a cohort of homosexual men with human immunodeficiency virus. J Acquir Immune Defic Syndr 1988;1:396-404.
14. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T-cell growth factor that interacts with the β-chain of the interleukin-2 receptor. Science 1994;264:965-8.
15. Carson et al. Endogenous production of interleukin-15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest 1995;96:2578-82.
16. + cell counts greater than 400 per cubic millimeter. N Engl J Med 1993;329:297-303.
17. Mulder J, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomised, double-blind, placebo controlled study. AIDS 1994;8:313-25.
18. + cell counts less than 300; preliminary results. J Infect Dis (in press).
19. + cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
20. 3. In: Program and Abstracts of the 2nd National Conference on Human Retroviruses and Related Infections. Washington DC, January, 1995: Abstract LB31.
21. De Jong M, and Dutch-Italian-Australian nevirapine study group. Antiviral response to nevirapine monotherapy in nucleoside naive persons. In: Program and Abstracts of the 10th International Conference on AIDS, Yokohama, Japan, August, 1994; Abstract PB0847.
22. Staszewski S, Vandercam B, de Vuyst H, et al. Evaluation of the efficacy and tolerance of R18893, R89439 (loviride) and placebo in patients infected with HIV-1. In: Abstracts of the 4th European Conference on Clinical Aspects and Treatment of HIV Infection, Milan, Italy, 16-March, 1994: Abstract O41.
23. Danner SA, Carr A, Leonard J, et al. Safety, pharmacokinetics and preliminary efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
24. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. In: Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington DC, USA, January, 1996: Abstract LB6a.
25. Carr A, Cooper DA. HIV protease inhibitors. AIDS 1996: 10 (suppl 1); (in press).
26. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
27. + lymphocytes. J Acquir Immune Defic Syndr 1993;6:142-53.
28. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.